Merck Sharp & Dohme 8-K Merck Announces Second-Quarter 2009 Financial Results

Exhibit 99.2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

SECOND QUARTER

2009

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	2Q ’09		2Q ’08		YTD 2009		YTD 2008
MERCK / SCHERING-PLOUGH	$	362.3	$	365.2	$	653.2	$	758.0
ASTRAZENECA LP		122.9		61.4		291.2		192.5
Other (1)		101.9		96.4		228.6		224.6
TOTAL	$	587.1	$	523.0	$	1,173.0	$	1,175.1

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur MSD and Johnson & Johnson°Merck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	2Q ’09		2Q ’08		YTD 2009		YTD 2008
FRONTLINE, other fipronil	$	279.5	$	306.1	$	586.4	$	647.7
BIOLOGICALS		188.2		208.5		360.1		382.9
IVOMEC, HEARTGARD, other avermectins		115.4		140.3		250.1		286.4
Other Animal Health		68.1		77.2		138.7		148.7
TOTAL MERIAL SALES	$	651.2	$	732.1	$	1,335.3	$	1,465.7
Sanofi Pasteur MSD	2Q ’09		2Q ’08		YTD 2009		YTD 2008
GARDASIL	$	144.9	$	234.2	$	309.0	$	474.0
OTHER VIRAL VACCINES		26.9		29.1		52.3		51.8
HEPATITIS VACCINES		11.0		19.4		24.4		37.4
ROTATEQ		10.1		7.3		18.8		13.3
Other Vaccines		120.3		140.0		252.0		264.9
TOTAL SANOFI PASTEUR MSD SALES	$	313.2	$	430.0	$	656.5	$	841.4
Merck / Schering-Plough Collaboration	2Q ’09		2Q ’08		YTD 2009		YTD 2008
VYTORIN	$	519.9	$	592.1	$	985.9	$	1,243.3
ZETIA		513.5		560.4		992.8		1,142.1
TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,033.4	$	1,152.5	$	1,978.7	$	2,385.4

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	2Q ’09			2Q ’08			YTD 2009			YTD 2008
INTEREST INCOME	$	(70.0	)	$	(143.4	)	$	(166.3	)	$	(313.0	)
INTEREST EXPENSE		99.5			50.6			160.2			123.2
EXCHANGE (GAINS) LOSSES		(20.0	)		8.7			(3.5	)		21.3
Other, net(1)		(5.9	)		(28.7	)		(54.0	)		(2,153.5	)
TOTAL	$	3.6		$	(112.8	)	$	(63.6	)	$	(2,322.0	)

⁽¹⁾ Other, net in the first six months of 2008 primarily reflects a $2.2 billion gain on distribution from AstraZeneca LP.

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

SECOND QUARTER

2009

NET PRODUCT SALES DETAIL (millions of dollars)

	2Q ’09 vs. 2Q ’08
PRODUCT	TOTAL % CHG			TOTAL $	U.S. % CHG			U.S. $	Foreign % CHG			Foreign $
COZAAR / HYZAAR		-4	%	906		5	%	332		-8	%	573
JANUVIA		38	%	462		33	%	348		59	%	115
JANUMET			*	155		68	%	113			*	41
SINGULAIR		16	%	1,257		16	%	823		17	%	434
Vaccines:
GARDASIL		-18	%	268		-28	%	184		18	%	84
ROTATEQ		-29	%	126		-35	%	107		58	%	18
ZOSTAVAX		-36	%	42		-36	%	42		N/A		—
OTHER VIRAL VACCINES(1)		1	%	322		4	%	303		-27	%	19
HEPATITIS VACCINES(2)		-24	%	29		-14	%	25		-56	%	4
OTHER VACCINES(3)		-24	%	53		-9	%	30		-37	%	23
Other Reported Products:
ARCOXIA		-15	%	88		N/A		—		-15	%	88
CANCIDAS		-7	%	149		-29	%	18		-3	%	130
COSOPT / TRUSOPT		-43	%	125		-87	%	11		-13	%	114
CRIXIVAN / STOCRIN		-30	%	56		-12	%	3		-30	%	53
EMEND		17	%	77		26	%	51		3	%	26
FOSAMAX		-33	%	277		-66	%	42		-18	%	236
INVANZ		—		71		9	%	37		-8	%	34
ISENTRESS			*	172		95	%	88			*	85
MAXALT		8	%	141		15	%	99		-6	%	42
PRIMAXIN		-21	%	160		-23	%	32		-20	%	128
PROPECIA		-2	%	106		-2	%	37		-1	%	69
PROSCAR		-8	%	79		-59	%	1		-6	%	78
TIMOPTIC / TIMOPTIC XE		-15	%	27			*	—		-9	%	27
VASOTEC / VASERETIC		-19	%	76		N/A		—		-19	%	76
ZOCOR		-20	%	141		-53	%	9		-16	%	132
ZOLINZA		46	%	4		48	%	4		19	%	—

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	2Q ’09		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	5,900	-3	%	1	2	-5
U.S. ($ MM)		3,251	-3	%	-7	5	N/A
Foreign ($ MM)		2,649	-2	%	11	-2	-11

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

JUNE YEAR-TO-DATE

2009

NET PRODUCT SALES DETAIL (millions of dollars)

	JUNE YTD ’09 vs. JUNE YTD ’08
	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
PRODUCT
COZAAR / HYZAAR	-2	%	1,745	4	%	636	-6	%	1,109
JANUVIA	44	%	873	35	%	661	83	%	213
JANUMET		*	283	75	%	214		*	69
SINGULAIR	6	%	2,315	6	%	1,505	6	%	809
Vaccines:
GARDASIL	-26	%	530	-34	%	363	-1	%	167
ROTATEQ	-29	%	260	-33	%	232	26	%	28
ZOSTAVAX	-16	%	118	-16	%	118	N/A		—
OTHER VIRAL VACCINES(1)	6	%	574	9	%	538	-28	%	37
HEPATITIS VACCINES(2)	-12	%	63	—		53	-46	%	10
OTHER VACCINES(3)	-24	%	108	-4	%	60	-39	%	49
Other Reported Products:
ARCOXIA	-14	%	169	N/A		—	-14	%	169
CANCIDAS	-7	%	287	-34	%	37	-1	%	250
COSOPT / TRUSOPT	-41	%	246	-85	%	25	-12	%	221
CRIXIVAN / STOCRIN	-32	%	105	-18	%	6	-33	%	99
EMEND	17	%	146	18	%	95	15	%	51
FOSAMAX	-39	%	539	-75	%	82	-18	%	456
INVANZ	5	%	132	12	%	70	-2	%	62
ISENTRESS		*	320		*	163		*	158
MAXALT	9	%	274	16	%	191	-5	%	83
PRIMAXIN	-20	%	324	-33	%	62	-16	%	262
PROPECIA	-2	%	209	-3	%	73	-1	%	136
PROSCAR	-12	%	151	-57	%	3	-10	%	149
TIMOPTIC / TIMOPTIC XE	-10	%	55	-86	%	1	-5	%	54
VASOTEC / VASERETIC	-19	%	153	N/A		—	-19	%	153
ZOCOR	-22	%	278	-63	%	18	-15	%	261
ZOLINZA	28	%	9	30	%	8	6	%	1

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	JUN YTD ’09		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	11,285	-5	%	-2	2	-4
U.S. ($ MM)		6,207	-6	%	-11	5	N/A
Foreign ($ MM)		5,078	-3	%	8	-2	-9